Endocrine Abstracts

The gut hormone glucagon-like peptide (GLP)-1 lowers blood glucose by stimulating meal-related insulin secretion and lowering hyperglucagonaemia in a glucose-dependent manner. Currently, injectable GLP-1 receptor agonists (GLP-1RA) and oral inhibitors of the dipeptidyl peptidase (DPP)-4 enzyme, that degrades native GLP-1, are successfully employed in the treatment of type 2 diabetes (T2DM). Clinically relevant extrapancreatic effects of GLP-1 (RA) involve slowing down gastric ...